

Johan A Karlsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4748758/publications.pdf>

Version: 2024-02-01

33
papers

489
citations

623734

14
h-index

713466

21
g-index

33
all docs

33
docs citations

33
times ranked

844
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients â€” baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice. <i>Arthritis Research and Therapy</i> , 2015, 17, 378.	3.5	53
2	Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1094-1101.	0.9	43
3	National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2163-2166.	0.9	37
4	Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 356-361.	0.9	28
5	A Multiâ€”Biomarker Disease Activity Score and the Choice of Secondâ€”Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure. <i>Arthritis and Rheumatology</i> , 2017, 69, 953-963.	5.6	27
6	Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1927-1933.	0.9	25
7	Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. <i>RMD Open</i> , 2016, 2, e000197.	3.8	21
8	Pain Over Two Years After Start of Biologic Versus Conventional Combination Treatment in Early Rheumatoid Arthritis: Results From a Swedish Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2021, 73, 1312-1321.	3.4	21
9	Realâ€”World Sixâ€”and Twelveâ€”Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. <i>Arthritis Care and Research</i> , 2022, 74, 1205-1218.	3.4	20
10	Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis: results from the SPARTAKUS cohort. <i>Rheumatology</i> , 2019, 58, 1176-1187.	1.9	18
11	Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis: Observational Data from Southern Sweden. <i>Journal of Rheumatology</i> , 2016, 43, 1292-1299.	2.0	17
12	Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT Trial. <i>Journal of Rheumatology</i> , 2019, 46, 555-563.	2.0	17
13	Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies. <i>Arthritis Research and Therapy</i> , 2019, 21, 266.	3.5	17
14	Chronic Pain and Assessment of Pain Sensitivity in Patients With Axial Spondyloarthritis: Results From the SPARTAKUS Cohort. <i>Journal of Rheumatology</i> , 2021, 48, 1672-1679.	2.0	17
15	Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 159-161.	0.9	15
16	<sc>Oneâ€”Year</sc> Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses. <i>Arthritis Care and Research</i> , 2022, 74, 748-758.	3.4	15
17	Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 3635-3645.	1.9	14
18	Patientâ€”Reported Outcomes Are More Important Than Objective Inflammatory Markers for Sick Leave in Biologicsâ€”Treated Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 1712-1716.	3.4	13

#	ARTICLE	IF	CITATIONS
19	Considerations for Evaluating and Recommending Worker Productivity Outcome Measures: An Update from the OMERACT Worker Productivity Group. <i>Journal of Rheumatology</i> , 2019, 46, 1401-1405.	2.0	13
20	EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1116-1123.	0.9	13
21	Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 42.	3.5	12
22	EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden. <i>Arthritis Research and Therapy</i> , 2016, 18, 51.	3.5	7
23	Validity of clinical psoriatic arthritis diagnoses made by rheumatologists in the Swedish National Patient Register. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 374-384.	1.1	7
24	Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden. <i>Rheumatology</i> , 2017, 56, kew473.	1.9	6
25	Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries. <i>Rheumatology</i> , 2023, 62, 647-658.	1.9	6
26	Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study. <i>Rheumatology</i> , 2021, 60, 140-146.	1.9	4
27	SAT0336â€¦CLINICAL DIAGNOSES OF AXIAL SPONDYLOARTHRITIS SHOW A HIGH OVERALL CONCORDANCE WITH CLASSIFICATION CRITERIA FULFILMENT, BUT ARE LESS CONSISTENT FOR DIFFERENTIATION BETWEEN SUBTYPES IN ESTABLISHED AXIAL DISEASE: RESULTS FROM THE SPARTAKUS COHORT. , 2019, , .		1
28	Response to: â€”response to: irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?â€” by Proft et al.. <i>Annals of the Rheumatic Diseases</i> , 2019, , annrheumdis-2019-216752.	0.9	1
29	How good is the agreement between clinical diagnoses and classification criteria fulfilment in axial spondyloarthritis? Results from the SPARTAKUS cohort. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 364-373.	1.1	1
30	THU0149â€¦PRIME-BOOSTER RESPONSE TO PNEUMOCOCCAL CONJUGATE AND POLYSACCHARIDE VACCINES IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. , 2019, , .		0
31	THU0073â€¦HAVE THE CLINICAL CHARACTERISTICS OF RHEUMATOID ARTHRITIS AT PRESENTATION BECOME MILDER OVER TIME? RESULTS FROM A NATIONWIDE STUDY OVER THREE DECADES IN SWEDEN. , 2019, , .		0
32	THU0090â€¦MORTALITY OVER UP TO 14 YEARS FOLLOW-UP IN MTX-REFRACTORY PATIENTS RANDOMIZED TO A STRATEGY STARTING WITH ADDITION OF INFLIXIMAB OR ADDITION OF SULFASALAZINE AND HYDROXYCHLOROQUINE. , 2019, , .		0
33	Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine. <i>Rheumatology</i> , 2021, 60, 2217-2222.	1.9	0